Targeting unique tumor antigens and modulating the cytokine environment may improve immunotherapy for tumors with immune escape mechanisms

被引:12
|
作者
Slingluff, CL [1 ]
机构
[1] Univ Virginia, Ctr Hlth Sci, Dept Surg, Charlottesville, VA 22906 USA
关键词
tumor antigens; cytokine environment; immunotherapy; escape mechanisms;
D O I
10.1007/s002620050588
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cytotoxic T-cell responses to shared tumor antigens have been characterized for several tumor types, and the MHC-associated peptides that comprise these antigens have been defined at a molecular level. These provide new tools to determine whether immune responses can be generated with these tumor antigens, and there are data to suggest that such immune responses can be generated. However, it is also clear that tumor cells can evade immune responses directed against some shared antigens, by downregulating expression of MHC or of the antigenic protein(s), as well as by more active methods such as secretion of immunosuppressive cytokines. Awareness of these mechanisms of immune escape will help to direct development of the next generation of tumor vaccines. Targeting unique antigens and modulating the cytokine environment likely will be critical to comprehensive vaccine systems in the future.
引用
收藏
页码:371 / 373
页数:3
相关论文
共 32 条
  • [21] HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activation
    Rodriguez, Josefa A.
    ONCOLOGY LETTERS, 2017, 14 (04) : 4415 - 4427
  • [22] Autologous tumor antigens and boron nanosheet-based nanovaccines for enhanced photo-immunotherapy against immune desert tumors
    Sun, Zhe
    Fan, Taojian
    Liu, Quan
    Huang, Luodan
    Hu, Weibin
    Shi, Lulin
    Wu, Zongze
    Yang, Qinhe
    Liu, Liping
    Zhang, Han
    NANOPHOTONICS, 2021, 10 (09) : 2519 - 2535
  • [23] How Risk Factors Affect Head and Neck Squamous Cell Carcinoma (HNSCC) Tumor Immune Microenvironment (TIME): Their Influence on Immune Escape Mechanisms and Immunotherapy Strategy
    Galizia, Danilo
    Minei, Silvia
    Maldi, Elena
    Chila, Giovanna
    Polidori, Alessio
    Merlano, Marco Carlo
    BIOMEDICINES, 2022, 10 (10)
  • [24] Immunogenomic signatures to predict outcome in ovarian and endometrial cancers: Potential strategies in targeting the tumor immune microenvironment to improve response to immunotherapy
    Mahdi, Haider
    Ni, Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [25] Tumor-targeting and activatable biomimetic nanococktails synergistically regulate immune responses for spatiotemporal immunotherapy of low immunogenic solid tumors
    Cui, Yongsheng
    Liu, Jing
    Cui, Lele
    Wei, Chaorong
    Xu, Mingxia
    Wu, Zhengzhong
    Guo, Yingkun
    Mi, Peng
    NANO TODAY, 2024, 57
  • [26] Unique tumor antigens: Evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy
    Sensi, Marialuisa
    Anichini, Andrea
    CLINICAL CANCER RESEARCH, 2006, 12 (17) : 5023 - 5032
  • [27] Targeting tumor-associated immune suppression with selective protein kinase A type I (PKAI) inhibitors may enhance cancer immunotherapy
    Hussain, Muzammal
    Shah, Zahir
    Abbas, Nasir
    Javeed, Aqeel
    Mukhtar, Muhammad Mahmood
    Zhang, Jiancun
    MEDICAL HYPOTHESES, 2016, 86 : 56 - 59
  • [28] Oncolytic Virus-Mediated Targeting of PGE2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy
    Hou, Weizhou
    Sampath, Padma
    Rojas, Juan J.
    Thorne, Steve H.
    CANCER CELL, 2016, 30 (01) : 108 - 119
  • [29] Synergistic cancer immunotherapy combination of MVA-CD40L with tumor targeting antibodies or checkpoint blockade to achieve strong antitumor immune responses against large, established tumors
    Medina-Echeverz, Jose
    Hinterberger, Maria
    Giessel, Raphael
    Bathke, Barbara
    Kassub, Ronny
    Fiore, Giovanna
    Chaplin, Paul
    Hochrein, Hubertus
    Lauterbach, Henning
    CANCER RESEARCH, 2019, 79 (13)
  • [30] TUMOR IMMUNITY TO MURINE PLASMA-CELL TUMORS .3. DETECTION OF COMMON AND UNIQUE TUMOR-ASSOCIATED ANTIGENS ON BALB-C, C3H, AND NZB PLASMACYTOMAS BY INVIVO AND INVITRO INDUCTION OF TUMOR-IMMUNE RESPONSES
    BURTON, RC
    WARNER, NL
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1977, 58 (03) : 701 - 709